Navigation Links
Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
Date:4/25/2013

CHESTERBROOK, Pa., April 25, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2013 on Monday, April 29, 2013 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 8:30 a.m. ET to discuss results and highlights of the first quarter.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 7:00 a.m. ET on Monday, April 29, 2013.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 8:30 a.m. ET on Monday, April 29, 2013.  A question and answer session will follow the presentation. 

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

Mr. Adrian Adams , Chief Executive Officer and President, will host the conference call.Conference call details: Date: Monday, April 29, 2013 Time:  8:30 a.m. ET Dial-in (U.S.):  866-515-2913 Dial-in (International): 617-399-5127 Web cast: http://www.auxilium.com Passcode: AUXILIUMTo access an audio replay of the call:Access number (U.S.):  888-286-8010 Access number (International):  617-801-6888Replay Passcode #: 98775073About Auxilium
Auxilium is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S.  GlaxoSmithKline LLC co- promotes Testim with Auxilium in the U.S.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA on November 6, 2012 and has been accepted for standard review with a PDUFA date of September 6, 2013. Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for CCH.  For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words.  Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2012,  filed with the Securities and Exchange Commission (the "SEC"). While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so.  Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov.  There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

Contacts:
James E. Fickenscher /CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr. / VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900 
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
3. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
4. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
5. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
6. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
7. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
9. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
11. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017 Provides understanding ... and agreements entered into by the worlds leading ... https://www.reportbuyer.com/product/3605699/ Description The Global Renal Failure ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/20/2017)... Systems Magnetic resonance imaging (MRI) ... the organs and tissues in the body with the ... technique does not use ionizing radiation either for the ... of cancer. MRI is used for a variety of ... orthopedics. Hence, MRI helps in the diagnosis and treatment ...
(Date:2/20/2017)... report analyzes the worldwide markets for Drug-Eluting Stents in US$ Million. ... Canada , Japan , Europe ... , and Rest of World. Read the ... ... 2015 through 2022. Also, a six-year historic analysis is provided for ...
Breaking Medicine Technology:
(Date:2/20/2017)... Mass. (PRWEB) , ... February 20, 2017 , ... ... delivery for regulated industries, announced Biscom Document Router (BDR), the first IoT device ... resolution lab diagnostics and imaging. Biscom will debut BDR at HIMSS17 ...
(Date:2/20/2017)... ... 2017 , ... Houston dentist , Dr. Nazari, announces ... his office, Antoine Dental Center. Emergency dentistry encompasses many treatments for emergencies affecting ... for serious complications and often experience severe pain. Not only does prompt treatment ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up ... facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift from ...
(Date:2/19/2017)... , ... February 19, 2017 , ... ... to result in better care, and MEDfx and the Delaware Health Information Network ... Delaware. , As the nation’s first state-wide health information exchange, DHIN stores and ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
Breaking Medicine News(10 mins):